Trademarkia Logo

Canada

C$
Trademark Search in Canada
MIQURE

View On IC.GC.CA

MIQURE
REGISTERED

on 17 Oct 2024

Last Applicant/ Owned by

UNIQURE IP B.V.

Paasheuvelweg 251105 BP Amsterdam

NL

Serial Number

1956320 filed on 9th Apr 2019

Registration Number

TMA1263503 registered on 17th Oct 2024

Registration expiry Date

17th Oct 2034

Correspondent Address

LAVERY, DE BILLY, LLP

1 Place Ville Marie, Suite 4000Montréal

QUÉBEC

CA

H3B4M4

MIQURE

Trademark usage description

medicinal preparations for the diagnosis, treatment or prevention of central nervous system diseases, liver diseases, neuromuscular diseases and cardi Read More

Classification Information

Class [005]
Medicinal preparations for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases, namely, viral systems, gene therapy systems, nucleic acid delivery systems, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors; Viral systems, gene therapy systems, nucleic acid delivery systems for medical purposes, namely, medicines for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases; Pharmaceutical preparations and substances for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, vaccines, prophylaxis medicines and other pharmaceutical preparations all for use in nucleic acid-based therapy, gene therapy and cell therapy for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases.

Classification kind code

11

Class [042]
Research, product development and consultancy in the field of medical biotechnology, pharmaceutical biotechnology, biologics, medical science, chemistry and biochemistry; Research and product development in the field of pharmaceutics.

Classification kind code

11

Class [044]
Gene therapy services, namely, gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders; Consultancy in the field of pharmaceutics.

Classification kind code

11

Mark Details

Serial Number

1956320

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 42
on 17th Jul 2024		Advertised
Submitted for opposition 27
on 24th Jun 2024		Approval Notice Sent
Submitted for opposition 26
on 24th Jun 2024		Approved
Submitted for opposition 15
on 14th Mar 2024		Correspondence Created
Submitted for opposition 22
on 5th Jul 2023		Search Recorded
Submitted for opposition 20
on 5th Jul 2023		Examiner's First Report
Submitted for opposition 287
on 11th Apr 2022		Pre-Assessment Letter Sent
Submitted for opposition 31
on 12th Apr 2019		Formalized
Submitted for opposition 1
on 10th Apr 2019		Created
Submitted for opposition 30
on 9th Apr 2019		Filed